MetaVia Inc.
About MetaVia Inc.
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$13.0M
- Total assets
- $11.1M
- Market cap
- $13.3M
- Operating margin
- -2687.8%
- Net margin
- -2543.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $510.0K
- Operating expenses
- $13.7M
- Operating income
- -$13.7M
- Income tax
- -$2.4M
- Net income
- -$13.0M
- EPS (basic)
- $-7.35
- EPS (diluted)
- $-7.35
Balance sheet
- Total assets
- $11.1M
- Current assets
- $10.9M
- Total liabilities
- $5.8M
- Current liabilities
- $5.6M
- Shareholders’ equity
- $5.3M
Cash flow
- Operating cash flow
- -$15.7M
- Investing cash flow
- -$2.0K
- Financing cash flow
- $10.0M
- Net cash flow
- -$5.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $13.3M
- EPS (diluted)
- $-7.35
- Shares outstanding
- 6.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 4, 2016
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $13.0M.
- Revenue declined 45% from FY2024 to FY2025.
- Trading 87% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review MetaVia Inc..
